TRAIL Suppresses Human Breast Cancer Cell Migration via MADD/CXCR7

  • Wang, Rui (Department of Breast and Thyroid Sugery, The First Affiliated Hospital of Liaoning Medical University) ;
  • Li, Jin-Cheng (Department of Breast and Thyroid Sugery, The First Affiliated Hospital of Liaoning Medical University)
  • Published : 2015.04.14


Background: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can specifically induce apoptosis limited to various cancer cells, so this reagent is considered a promising medicine for cancer therapy. TRAIL also exerts effects on non-apoptotic signals, relevant to processes such as metastasis, autophagy and proliferation in cancer cells. However, the mechanisms of TRAIL-regulated non-apoptotic signals are unclear. The purpose of this study was to investigate MADD/CXCR7 effects in TRAIL-mediated breast cancer cell migration. Materials and Methods: The ability of MADD/CXCR7 to regulate MVP signaling in TRAIL-mediated breast cancer cells migration was evaluated by transwell migration assay, quantitative RT-PCR, Western blotting and knock down experiments. Results: In this study, we found that treatment with TRAIL resulted in induced expression levels of MADD and CXCR7 in breast cancer cells. Knock down of MADD followed by treatment with TRAIL resulted in increased cell migration compared to either treatment alone. Similarly, through overexpression and knockdown experiments, we demonstrated that CXCR7 also positively regulated TRAIL-inhibited migration. Surprisingly, knock down of MADD lead to inhibition of TRAIL-induced CXCR7 mRNA and protein expression and overexpression of CXCR7 lead to the reduction of MADD expression, indicating that MADD is an upstream regulatory factor of TRAIL-triggered CXCR7 production and a negative feedback mechanism between MADD and CXCR7. Furthermore, we showed that CXCR7 is involved in MADD-inhibited migration in breast cancer cells. Conclusions: Our work defined a novel signaling pathway implicated in the control of breast cancer migration.




  1. Aiuti A, Webb J, Bleul C, et al (1997). The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med, 185, 111-20.
  2. Al-Zoubi AM, Efimova EV, Kaithamana S, et al (2001). Contrasting effects of IG20 and its splice isoforms, MADD and DENN-SV, on tumor necrosis factor alpha-induced apoptosis and activation of caspase-8 and -3. J Biol Chem, 276, 47202-11.
  3. Attar R, Sajjad F, Qureshi MZ, et al (2014). TRAIL based therapy: overview of mesenchymal stem cell based delivery and miRNA controlled expression of TRAIL. Asian Pac J Cancer Prev, 15, 6495-7.
  4. Azijli K, Weyhenmeyer B, Peters GJ, et al (2013). Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death Differentiation, 20, 858-68.
  5. Azijli K, Yuvaraj S, Peppelenbosch MP, et al. (2012). Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells. J Cell Science, 125, 4651-61.
  6. Burns JM, Summers BC, Wang Y, et al (2006). A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. The J Experimental Med, 203, 2201-13.
  7. Efimova EV, Al-Zoubi AM, Martinez O, et al (2004). IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs. Oncogene, 23, 1076-87.
  8. Falschlehner C, Emmerich CH, Gerlach B, et al (2007). TRAIL signalling: decisions between life and death. Int J Biochem Cell Biology, 39, 1462-75.
  9. Grymula K, Tarnowski M, Wysoczynski M, et al (2010). Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas. Int J Cancer, 127, 2554-68.
  10. Hernandez L, Magalhaes MA, Coniglio SJ, et al (2011). Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Res, 13, 128.
  11. Iwakiri S, Mino N, Takahashi T, et al (2009). Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer. Cancer, 115, 2580-93.
  12. Kakinuma T, Hwang ST (2006). Chemokines, chemokine receptors, and cancer metastasis. J Leukocyte Biol, 79, 639-51.
  13. Kruyt FA (2008). TRAIL and cancer therapy. Cancer Letters, 263, 14-25.
  14. Kurada BR, Li LC, Mulherkar N, et al (2009). MADD, a splice variant of IG20, is indispensable for MAPK activation and protection against apoptosis upon tumor necrosis factor-alpha treatment. J Biological Chemistry, 284, 13533-41.
  15. Mulherkar N, Ramaswamy M, Mordi DC, et al (2006). MADD/DENN splice variant of the IG20 gene is necessary and sufficient for cancer cell survival. Oncogene, 25, 6252-61.
  16. Nogueira DR, Yaylim I, Aamir Q, et al (2014). TRAIL mediated signaling in pancreatic cancer. Asian Pac J Cancer Prev, 15, 5977-82.
  17. Pablos JL, Amara A, Bouloc A, et al (1999). Stromal-cell derived factor is expressed by dendritic cells and endothelium in human skin. Am J Pathol, 155, 1577-86.
  18. Riddick E, Evans S, Rousch J, et al (2013). Identification of death receptors DR4 and DR5 in HTB-12 astrocytoma cell lines and determination of TRAIL sensitivity. J Solid Tumors, 3, 20-26.
  19. Schievella AR, Chen JH, Graham JR, et al (1997). MADD, a novel death domain protein that interacts with the type 1 tumor necrosis factor receptor and activates mitogen-activated protein kinase. J Biol Chem, 272, 12069-75.
  20. Shi J, Zheng D, Man K, et al (2003). TRAIL: a potential agent for cancer therapy. Current molecular medicine, 3, 727-736.
  21. Smith CW, Valcarcel J (2000). Alternative pre-mRNA splicing: the logic of combinatorial control. Trends Biochem Sci, 25, 381-8.
  22. Srivastava RK, Kurzrock R, Shankar S (2010). MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Molecular Cancer Therapeutics, 9, 3254-66.
  23. Szliszka E, Mazur B, Zydowicz G, et al (2009). TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells. Folia Histochem Cytobiol, 47, 579-85.
  24. Tachibana K, Hirota S, Iizasa H, et al (1998). The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature, 393, 591-4.
  25. Thelen M, Thelen S (2008). CXCR7, CXCR4 and CXCL12: an eccentric trio? J Neuroimmunol, 198, 9-13.
  26. Turner A, Li LC, Pilli T, et al (2013). MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells. PloS One, 8, 56817.
  27. Wang D, Liu D, Gao J, et al (2013). TRAIL-induced miR-146a expression suppresses CXCR4-mediated human breast cancer migration. The FEBS J, 280, 3340-53.
  28. Wang H, Xu C, Kong X, et al (2014). Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer. PloS One, 9, 99067.
  29. Zabel BA, Wang Y, Lewen S, et al (2009). Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J Immunol, 183, 3204-11.
  30. Zheng K, Li HY, Su XL, et al (2010). Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Cancer Res, 29, 31.

Cited by

  1. Novel recombinant protein FlaA N/C increases tumor radiosensitivity via NF-κB signaling in murine breast cancer cells vol.12, pp.4, 2016,